hotspot -WSS

hotspot

author：comprehensive 2025-10-03 00:39:36 - browse：54226

Cambridge: AbbVie — Ruby Wallau for STAT

AbbVie will pay $10 billion for the biotech firm Immunogen, the company said Thursday, acquiring an approved treatment for ovarian cancer and buying into a burgeoning area of oncology.

Under the agreement, AbbVie will pay $31.26 per share in cash for Immunogen, a nearly 100% premium to the company’s recent trading price. Central to the deal, expected to close in the middle of next year, is Elahere, an Immunogen product that won Food and Drug Administration approval for advanced ovarian cancer in 2022.

Elahere is among a surging class of cancer medicines called antibody-drug conjugates, or ADCs, which are designed to deliver a targeted dose of chemotherapy directly to tumor cells while sparing healthy tissues. AbbVie’s acquisition is the latest multibillion-dollar deal in the space, following Merck’s $22 billion agreement with ADC specialist Daiichi Sankyo and Pfizer’s $43 billion buyout of Seagen earlier this year.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Food as medicine: CMS rules hamper 'prescribing' of fruits, veggies
Next article： Living with Hashimoto's and celiac disease, and med school, too

WSS

How digital tools helped lower hypertension in marginalized patients

Medical mystery: When a cough is not just a cough

Industry veterans launch new biotech VC with $310M

New definition of a human embryo proposed amid rapid advances

ActiGraph execs on goal of drug approvals with digital endpoints

A ‘polypill’ could sharply reduce cardiovascular disease in the U.S.

knowledge

hotspot

explore

Dobbs anniversary: the lost opportunity of abortion as health care

Robert F. Kennedy is pitching centrism on health, even on abortion

Psychedelics group wrestles with new pharma identity

Vaccine advisory panel ACIP left half staffed by HHS

What does generative AI mean for health care? We asked experts

PhRMA lawsuit over Medicare drug price negotiation tossed

Wildfire smoke exposes gaps in outdoor worker protections

The dental labor crisis is a moment of opportunity

Medical leaders decry Supreme Court decision on affirmative action

'Revelatory' study finds a smoking impact that remains after quitting

hotspot

The pain doctors face in trying to build their families

FDA approves first treatment for ultra

Readout Newsletter: Biogen, Rocket Pharma, KalVista, and more

Readout Newsletter: Biogen, Rocket Pharma, KalVista, and more

Why did Pfizer dish out millions for a Super Bowl ad?

The dental labor crisis is a moment of opportunity

knowledge

focus

focus

focus